GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:GBLX
- CUSIP: N/A
- Web: growblox.com/
Capitalization:- Market Cap: $34.45 million
- Outstanding Shares: 127,746,000
Average Prices:- 50 Day Moving Avg: $0.25
- 200 Day Moving Avg: $0.28
- 52 Week Range: $0.21 - $0.65
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
Sales & Book Value:- Annual Revenue: $54,099.00
- Price / Sales: 636.85
- Book Value: $0.06 per share
- Price / Book: 4.73
Profitability:- EBIDTA: ($10,010,000.00)
- Net Margins: -5,761.07%
- Return on Equity: -158.06%
- Return on Assets: -100.57%
Misc:- Average Volume: 296,694 shs.
Frequently Asked Questions for GB Sciences (OTCMKTS:GBLX)
What is GB Sciences' stock symbol?
GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."
How were GB Sciences' earnings last quarter?
GB Sciences Inc (OTCMKTS:GBLX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. GB Sciences had a negative net margin of 5,761.07% and a negative return on equity of 158.06%. View GB Sciences' Earnings History.
Who are some of GB Sciences' key competitors?
Some companies that are related to GB Sciences include PURE Bioscience (PURE), PERPETUAL ENERGY I COM NPV (POST REV SPLIT) (PMGYF), Capricor Therapeutics (CAPR), IntelGenx Technologies Corp. (IGXT), Invivo Therapeutics Holdings Corp (NVIV), OmniComm Systems (OMCM), One Group Hospitality (STKS), OptimizeRx Corp. (OPRX), Generation Next Franchise Brands (VEND), HealthWarehouse.com (HEWA), Genius Brands International (GNUS), Abengoa Sa (ABGOY), Trimel Pharmaceuticals Corp. (TRLPF), Omni-Lite Industries Canada (OLNCF), Deep Down (DPDW), Noble Roman's (NROM), Trxade Group (TRXD) and Sierra Monitor Corp. (SRMC).
Who are GB Sciences' key executives?
GB Sciences' management team includes the folowing people:
- John Poss, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer
- Leslie Bocskor, Vice Chairman of the Board
- Ksenia Griswold, Chief Financial Officer, Vice President
- Andrea Small-Howard Ph.D., Chief Science Officer, Director
- Shane Terry, Independent Director
How do I buy GB Sciences stock?
Shares of GB Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GB Sciences' stock price today?
One share of GB Sciences stock can currently be purchased for approximately $0.27.
MarketBeat Community Rating for GB Sciences (OTCMKTS GBLX)MarketBeat's community ratings are surveys of what our community members think about GB Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for GB Sciences (OTCMKTS:GBLX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for GB Sciences (OTCMKTS:GBLX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for GB Sciences (OTCMKTS:GBLX)Earnings History by Quarter for GB Sciences (OTCMKTS GBLX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2016 | Q2 2017 | | ($0.04) | | | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for GB Sciences (OTCMKTS:GBLX)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for GB Sciences (OTCMKTS:GBLX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GB Sciences (OTCMKTS:GBLX)Insider Trades by Quarter for GB Sciences (OTCMKTS:GBLX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/4/2017 | Craig Ellins | Insider | Sell | 100,000 | $0.26 | $26,000.00 | |
| 10/6/2016 | Lazarus Management Co Llc | Major Shareholder | Sell | 785,000 | $0.31 | $243,350.00 | |
| 10/8/2014 | Lazarus Management Co Llc | Major Shareholder | Buy | 77,700 | $0.69 | $53,613.00 | |
| 10/2/2014 | Lazarus Management Co Llc | Major Shareholder | Buy | 39,605 | $0.85 | $33,664.25 | |
| 9/29/2014 | Lazarus Management Co Llc | Major Shareholder | Buy | 64,000 | $0.90 | $57,600.00 | |
| 9/17/2014 | Lazarus Management Co Llc | Major Shareholder | Buy | 47,640 | $0.76 | $36,206.40 | |
| 8/27/2014 | Israel Opportunities F Lazarus | Major Shareholder | Buy | 46,625 | $1.05 | $48,956.25 | |
| 8/1/2014 | Israel Opportunities F Lazarus | Major Shareholder | Buy | 39,800 | $1.24 | $49,352.00 | |
| 7/30/2014 | Israel Opportunities F Lazarus | Major Shareholder | Buy | 87,077 | $1.24 | $107,975.48 | |
| 7/2/2014 | Lazarus Investment Partners Ll | Major Shareholder | Buy | 269,632 | $1.19 | $320,862.08 | |
| 6/2/2014 | Lazarus Management Co Llc | Major Shareholder | Buy | 1,000,000 | $0.50 | $500,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for GB Sciences (OTCMKTS:GBLX)
Latest Headlines for GB Sciences (OTCMKTS:GBLX)
| Source: |
|
| Date | Headline |
|---|
 | Innovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis Plant
finance.yahoo.com - September 18 at 6:30 PM |
| Groundbreaking Collaboration Between A Major University And A Medical Cannabis Company
finance.yahoo.com - September 18 at 6:30 PM |
 | GB Sciences Inc (GBLX) Insider Sells $26,000.00 in Stock
www.americanbankingnews.com - August 7 at 8:02 PM |
| GB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis Market
finance.yahoo.com - August 2 at 7:49 PM |
 | GB Sciences initiates cannabis-based therapy clinical trials consulting services agreement with Worldwide Clinical Trials
seekingalpha.com - July 17 at 9:30 AM |
| GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.
finance.yahoo.com - July 17 at 9:30 AM |
| GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products
finance.yahoo.com - July 10 at 6:53 AM |
| Cannabis Industry Weekly Recap 7/7/2017
finance.yahoo.com - July 8 at 10:59 AM |
| GB Sciences Sells First Cannabis Harvest and Officially Enters Revenue Mode
finance.yahoo.com - July 5 at 7:32 AM |
| GB Sciences Wins Louisiana State University (LSU) Bid to Act as LSU Agricultural Center's Exclusive Operator of Medical Cannabis Production Facility
finance.yahoo.com - June 26 at 9:34 AM |
| GB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media
finance.yahoo.com - June 16 at 6:05 PM |
| GB Sciences Announced As LSU Bid Winner
finance.yahoo.com - June 16 at 6:05 PM |
| GB Sciences Files Patent Application for Chronic Pain and Heart Therapies
finance.yahoo.com - May 23 at 11:51 AM |
| GB Sciences Celebrates Their First Las Vegas Harvest
finance.yahoo.com - May 16 at 11:37 AM |
| GB Sciences Revered Founder, Craig Ellins, Retires
finance.yahoo.com - May 9 at 11:37 AM |
 | Cannabis, CBD, Vape Products See Uptick in Sales in Thriving Legal Marijuana Markets
www.prnewswire.com - May 4 at 12:14 PM |
| GB Sciences Surpasses Key Corporate Milestones, Plus Exclusive CEO Interview -- CFN Media
finance.yahoo.com - May 2 at 7:08 PM |
| GB Sciences Partners with Kush Cups to Produce Cannabis-Infused Keurig-Compatible K-Cups, Brewed Coffee and Infused Tea
finance.yahoo.com - April 10 at 11:26 AM |
| GB Sciences Submits Offer to Louisiana State University (LSU) for Providing the Cultivation, Extraction, Processing and Production of Medical Cannabis Pursuant to the Alison Neustrom Act
finance.yahoo.com - April 3 at 5:35 PM |
| GB Sciences Moves Closer to Clinical Trials -- CFN Media
finance.yahoo.com - March 28 at 11:41 AM |
 | Marijuana Stocks: How CEOs Can Navigate Market Volatility (And Survive Spicer And Sessions)
www.benzinga.com - March 10 at 11:30 PM |
| Why Cannabinoids Work Best Together -- CFN Media
finance.yahoo.com - March 7 at 11:27 AM |
| GROWBLOX SCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement
biz.yahoo.com - February 16 at 5:19 PM |
| GB Sciences Embraces Cannabinoid Complexities, Plus New Interview -- CFN Media
finance.yahoo.com - February 9 at 6:00 PM |
| GB Sciences Files Patent Application for the Treatment of Chronic Arthritis, Crohn's Disease, Inflammatory Bowel Disease, and Asthma; Proprietary Cannabinoid-Containing Complex Mixtures for the Treatment of Inflammatory Disorders
finance.yahoo.com - February 6 at 11:13 AM |
| GB Sciences Resets: Exclusive Executive Interview with CFN Media
finance.yahoo.com - January 23 at 10:27 AM |
| Leveraging the Cultivation and Medicinal Value of Cannabis - GB Sciences
finance.yahoo.com - January 18 at 5:47 PM |
| GB Sciences (GBLX): A Grow Business with a Moonshot in Biopharma -- CFN Media
finance.yahoo.com - January 6 at 5:54 PM |
| GB Sciences Announces Opening of Las Vegas, Nevada, Indoor Cannabis Grow, Moving GB Sciences into a Revenue Generating Stage
finance.yahoo.com - January 4 at 4:35 PM |
| GROWBLOX SCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
biz.yahoo.com - December 20 at 9:47 PM |
| GB Sciences, Inc. Engages CFN Media to Cultivate Long Term Investor Audience
finance.yahoo.com - December 15 at 5:56 PM |
| GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease
finance.yahoo.com - December 13 at 11:06 AM |
| Cannabis Stocks Stay Ahead In Exploding Legal Marijuana Market
www.prnewswire.com - November 29 at 5:07 PM |
 | Cannabis Legalization at the Forefront this Week
www.bizjournals.com - November 9 at 11:07 AM |
 | Pot is on the Ballot in Election 2016, but Investors Should Proceed with Caution
www.thestreet.com - October 27 at 9:50 AM |
| GROWBLOX SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - October 15 at 9:58 AM |
| Growblox Sciences Announces Patent Application for Treatments of Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Dementia
finance.yahoo.com - October 12 at 10:10 AM |
| Letter from CEO of Growblox Sciences Regarding Annual Meeting of Shareholders
finance.yahoo.com - October 11 at 5:24 PM |
| Growblox Sciences, Inc. Acquires Two Additional Medical Cannabis Cultivation And Production Establishment Licenses In The State Of Nevada
finance.yahoo.com - October 4 at 9:58 AM |
| Awareness Continues to Grow for Medical Uses of Cannabis
www.prnewswire.com - September 29 at 10:10 AM |
| GROWBLOX SCIENCES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
biz.yahoo.com - September 9 at 4:59 PM |
| GROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi
biz.yahoo.com - August 11 at 5:24 PM |
| Growblox Sciences, Inc. with Pacific Leaf Partners LLC, Announces Ownership of Flagship Teco Medical Cannabis Growing Facility
finance.yahoo.com - July 26 at 8:30 AM |
| Letter To Growblox Sciences, Inc. Shareholders From Its CEO
finance.yahoo.com - July 25 at 8:30 AM |
| Growblox Sciences Forms Growblox Life Sciences, LLC, A Research Organization Focused on Medical Cannabis Scientific Discoveries
finance.yahoo.com - July 19 at 9:30 AM |
| GROWBLOX SCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - July 14 at 5:31 PM |
| Growblox Sciences, Inc. Announces The Opening Of Its First Medical Marijuana Dispensary: "Showgrow" In Las Vegas, Nevada
finance.yahoo.com - June 28 at 9:30 AM |
| GROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - June 7 at 5:17 PM |
| GrowBLOX Sciences, Inc. Announces Exclusive Rights To Kyle Kushman's Cannabis Brands, Strains And Genetics In The State Of Nevada
finance.yahoo.com - June 7 at 9:48 AM |
GB Sciences (GBLX) Chart for Monday, September, 25, 2017
